This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ikegami, T. Articles by Weber, G. Search for Related Content PubMed PubMed Citation Articles by Ikegami, T. Articles by Weber, G.

Decreased Concentration of Xanthine Dehydrogenase (EC 1.1.1.204) in Rat Hepatomas¹

Laboratory for Experimental Oncology, Indiana University School of Medicine, Indianapolis, Indiana 46223

Xanthine dehydrogenase (EC 1.1.1.204), the rate-limiting enzyme of purine degradation, was purified 642-fold to homogeneity from liver of male Wistar rats. Antibody was generated to the purified enzyme in white rabbits and was partially purified. For the immunotitration a radioassay of high sensitivity was developed to determine low enzyme activities. Titration curves with the antibody showed that the xanthine dehydrogenase enzyme protein amounts in slowly growing hepatoma 20 and rapidly growing hepatoma 3924A were 34 and 4% of those of normal liver, which was in good agreement with the decrease in the activity of the enzyme to 33 and 2%, respectively. The contents of flavin adenine dinucleotide, the essential cofactor of the enzyme, in the immunoprecipitates in hepatomas 20 and 3924A were 27 and 4% of that of the normal liver. This is the first report to provide immunological evidence that a decreased enzyme activity in rat hepatomas, that of xanthine dehydrogenase, was due to a decrease in the enzyme protein amount. The markedly decreased xanthine dehydrogenase activity and amount have far-reaching biochemical and pharmacological implications for the tumors.

¹ Supported by USPHS Grants CA-13526 and CA-05034 awarded by the National Cancer Institute, Department of Health and Human Services.

² To whom requests for reprints should be addressed, at Laboratory for Experimental Oncology, Indiana University School of Medicine, 702 Barnhill Drive, Indianapolis, IN 46223.

Received 2/20/86. Accepted 4/25/86.

This article has been cited by other articles:

				N Linder, C Haglund, M Lundin, S Nordling, A Ristimaki, A Kokkola, J Mrena, J-P Wiksten, and J Lundin Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer. J. Clin. Pathol., September 1, 2006; 59(9): 965 - 971. [Abstract] [Full Text] [PDF]

				C. E. Griguer, C. R. Oliva, E. E. Kelley, G. I. Giles, J. R. Lancaster Jr., and G. Y. Gillespie Xanthine Oxidase-Dependent Regulation of Hypoxia-Inducible Factor in Cancer Cells Cancer Res., February 15, 2006; 66(4): 2257 - 2263. [Abstract] [Full Text] [PDF]

				N. Linder, J. Lundin, J. Isola, M. Lundin, K. O. Raivio, and H. Joensuu Down-Regulated Xanthine Oxidoreductase Is a Feature of Aggressive Breast Cancer Clin. Cancer Res., June 15, 2005; 11(12): 4372 - 4381. [Abstract] [Full Text] [PDF]